Jong-Seok Lee
Affiliations: | University of Maryland, College Park, College Park, MD |
Area:
PharmacyGoogle:
"Jong-Seok Lee"Mean distance: 16.22 (cluster 11) | S | N | B | C | P |
Cross-listing: Neurotree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kim KJ, Kim JW, Sung JH, et al. (2020) PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Scientific Reports. 10: 12308 |
| Lim SM, Kim SW, Cho BC, et al. (2020) Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| Han J, Ahn M, Kim S, et al. (2020) ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI). Journal of Clinical Oncology. 38: 9601-9601 |
| Lee KH, Ahn M, Han J, et al. (2020) Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study. Journal of Clinical Oncology. 38: 9572-9572 |
| Kim S, Ahn M, Han J, et al. (2020) Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study. Journal of Clinical Oncology. 38: 9571-9571 |
| Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. (2020) Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. Journal of Clinical Oncology. 38: 9500-9500 |
| Horn L, Liu SV, Mansfield AS, et al. (2020) Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC) Cancer Research. 80 |
| Kwon JH, Kim KJ, Sung JH, et al. (2019) Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. Cells. 8 |
| Kim DW, Lee DH, Han JY, et al. (2019) Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer (Amsterdam, Netherlands). 135: 66-72 |
| Segal NH, Wainberg ZA, Overman MJ, et al. (2019) Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors. Journal of Clinical Oncology. 37: 670-670 |